Sona Nanotech Inc. is a nanotechnology life sciences company focused on developing targeted therapies for cancer treatment. While it has a manageable current ratio and low debt-to-equity ratio, indicating some liquidity strength, the negative ROE and ROA raise concerns about profitability and operational efficiency. The stock price has seen a recent uptick, but the overall financial health score of 55 suggests potential challenges ahead. Investors should weigh the promising technology against the current financial struggles.
Loading financial metrics...
Company has $731K in cash but burned $587K last quarter. At this burn rate, only 1.2 quarters of runway remain without additional financing.
Company posted a loss of $-2.9M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $2.3M over the last year.
Strong balance sheet with net cash position provides cushion for growth investments.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Diagnostics & Research companies of a similar size
Based on 2025-Q2 (April 30, 2025)